Disclosed is a method comprising acquiring a value relating to VEGF-A of a subject, wherein the value is a measured value of total VEGF-A in a blood sample, or a value obtained by dividing a measured value of VEGF-A.sub.165b in the blood sample by a measured value of total VEGF-A in the blood sample (VEGF-A.sub.165b/total VEGF-A), and the value suggests prognosis of myocardial infarction of the subject or severity of coronary artery disease of the subject.

Disclosed is a method comprising acquiring a value relating to VEGF-A of a subject, wherein the value is a measured value of total VEGF-A in a blood sample, or a value obtained by dividing a measured value of VEGF-A.sub.165b in the blood sample by a measured value of total VEGF-A in the blood sample (VEGF-A.sub.165b/total VEGF-A), and the value suggests prognosis of myocardial infarction of the subject or severity of coronary artery disease of the subject.

The preparation and use of systems to provide surrogate whole blood controls using coagulation modifiers to simulate human whole blood in coagulation assays are disclosed.

The preparation and use of systems to provide surrogate whole blood controls using coagulation modifiers to simulate human whole blood in coagulation assays are disclosed.

A method to make it possible to obtain a value related to the amount of DD by FDP measurement. The method includes optically measuring a first calibration sample prepared from an FDP measurement reagent and a first calibrator containing D-dimer (DD) and having a first value relating to the ratio of the content of fibrin/fibrinogen degradation product FDP to the content of DD, acquiring first calculation data based on temporal change of optical information obtained by optical measurement of the first calibration measurement sample, performing optical measurement of a second calibration measurement sample prepared from FDP measurement reagent and a second calibrator containing DD and having a second value that is different from the first value related to the ratio of the content of FDP to the content of DD, acquiring second calculated data based on a temporal change in optical information obtained by optical measurement of the second calibration measurement sample, and acquiring calibration curve information indicating the relationship between the calculation data and the value relating to the amount of DD based on the first calculation data, the second calculation data, the first value, and the second value.

A method to make it possible to obtain a value related to the amount of DD by FDP measurement. The method includes optically measuring a first calibration sample prepared from an FDP measurement reagent and a first calibrator containing D-dimer (DD) and having a first value relating to the ratio of the content of fibrin/fibrinogen degradation product FDP to the content of DD, acquiring first calculation data based on temporal change of optical information obtained by optical measurement of the first calibration measurement sample, performing optical measurement of a second calibration measurement sample prepared from FDP measurement reagent and a second calibrator containing DD and having a second value that is different from the first value related to the ratio of the content of FDP to the content of DD, acquiring second calculated data based on a temporal change in optical information obtained by optical measurement of the second calibration measurement sample, and acquiring calibration curve information indicating the relationship between the calculation data and the value relating to the amount of DD based on the first calculation data, the second calculation data, the first value, and the second value.

Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.

The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.